サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1421496

欧州の次世代IVD市場：分析と予測（2023年～2033年）

Europe Next Generation IVD Market: Analysis and Forecast, 2023-2033
出版日: | 発行: BIS Research | ページ情報: 英文 117 Pages | 納期: 1～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
欧州の次世代IVD市場：分析と予測（2023年～2033年）
出版日: 2024年02月07日
発行: BIS Research
ページ情報: 英文 117 Pages
納期: 1～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の次世代IVDの市場規模は、2023年に242億米ドルとなりました。

同市場は、2023年から2033年にかけて5.26%のCAGRで拡大し、2033年には404億1,000万米ドルに達すると予測されています。診断における新技術とイノベーションの活用は、次世代IVD（体外診断）市場の拡大を刺激する力を持っています。分子診断学、ゲノミクス、次世代シーケンシング（NGS）は、この成長の主要な推進力になると予想され、疾患診断の強化のための新たな機会を提供し、その結果、患者の転帰を再構築します。

主要市場統計
予測期間 2023年～2033年
2023年の評価額 242億米ドル
2033年予測 404億1,000万米ドル
CAGR 5.26%

欧州の次世代IVD（体外診断薬）市場は著しい成長と変貌を遂げています。同市場には、同地域のヘルスケアに革命をもたらす多様な先端診断技術やツールが含まれています。この市場を牽引する主な要因としては、慢性疾患の蔓延、個別化医療に対する需要の高まり、疾患の早期発見と早期管理の重視の高まりなどが挙げられます。分子診断、ゲノミクス、次世代シーケンシング（NGS）は技術革新の最前線にあり、医療従事者が患者の状態について正確な洞察を得ることを可能にしています。これらの技術は、がん、感染症、遺伝性疾患を含む様々な疾患の診断において、精度、スピード、効率の向上を提供します。

さらに、欧州市場は活発な研究開発活動を特徴としており、IVDソリューションの継続的な進歩を促進しています。規制当局の支援と厳格な品質基準により、これらの診断薬の安全性と有効性が保証されています。患者の転帰の改善と医療資源の最適化に重点を置く欧州の次世代IVD市場は、継続的な成長とイノベーションの態勢を整えており、同地域の全体的なヘルスケアの向上に貢献しています。

当レポートでは、欧州の次世代IVD市場について調査し、市場の概要とともに、タイプ別、エンドユーザー別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場

  • 市場範囲
  • 調査手法

第2章 市場概要

  • イントロダクション
    • 次世代IVD市場の展望
    • 市場規模と成長の可能性
    • 次世代体外診断薬市場別の製品ベンチマーク（タイプ別）
  • COVID-19による次世代IVD市場への影響

第3章 業界分析

  • 法的要件
    • 欧州の法的要件と枠組み

第4章 市場力学

  • 概要
  • 影響分析
  • 市場の促進要因
  • 市場の課題
  • 市場の機会

第5章 次世代IVD市場、地域別、100万米ドル、2022年～2033年

  • 概要
  • 欧州
    • 市場力学
    • 市場規模と予測

第6章 企業プロファイル

  • bioMerieux SA（BioFire Diagnostics）
  • F. Hoffmann-La Roche Ltd.（Roche Molecular Systems, Inc.）
  • QIAGEN N.V.
  • Siemens Healthineers AG
図表

List of Figures

  • Figure 1: Facts about Europe Next-Generation IVD Market
  • Figure 2: Equipment's used for Next-Generation In-Vitro Diagnostics
  • Figure 3: Europe Next-Generation IVD Market, $Billion, 2022 and 2033
  • Figure 4: Trend Analysis of Next-Generation In-vitro Diagnostics Ecosystem
  • Figure 5: Common Chronic Conditions for Population Above 65 years
  • Figure 6: Key Challenges in the Europe Next-Generation IVD Market based on Primary Respondents
  • Figure 7: New In-Vitro Diagnostics Regulations (IVDR) and Medical Device Regulation (MDR)
  • Figure 8: Major Highlights Witnessed in the Next-Generation IVD Market During COVID-19 Impact
  • Figure 9: Role of POC Diagnostics in Next-Generation IVD Market During Pandemic
  • Figure 10: Leading and Emerging Companies in the Next-Generation IVD Ecosystem
  • Figure 11: Leading Companies in the Next-Generation IVD Ecosystem and Their Market Share (%)
  • Figure 12: Key Developments Undertaken by Companies in the Next-Generation IVD Market, July 2019-June 2023
  • Figure 13: Product Benchmarking of Next-Generation In-Vitro Diagnostics Ecosystem (by Test)
  • Figure 14: Europe Next-Generation IVD Market (by Type), Share (%), 2022 and 2033
  • Figure 15: Europe Next-Generation IVD Market (by End User), Share (%), 2022 and 2033
  • Figure 16: Europe Next-Generation IVD Market, Market Snapshot
  • Figure 17: Next-Generation IVD Market: Research Methodology
  • Figure 18: Primary Research Methodology
  • Figure 19: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 20: Top-Down Approach (Segment-Wise Analysis)
  • Figure 21: Europe Next-Generation IVD Market, $Billion, 2022-2033
  • Figure 22: Product Benchmarking of Next-Generation In-vitro Diagnostics Market (by Type)
  • Figure 23: In-Vitro Diagnostic Trends during the COVID-19 Pandemic
  • Figure 24: Timeline of IVDR 2017/746
  • Figure 25: Next-Generation IVD Market Dynamics
  • Figure 26: Factors Contributing to Growing Demand of POC Testing
  • Figure 27: Current Trend in In-Vitro Diagnostics: From Centralized Laboratory to Point-of-Care Testing
  • Figure 28: Annual Mortality by Chronic Illness in 1990, 2002, and 2020
  • Figure 29: Trend in COVID-19 Diagnostic Test Development and the Used Technology
  • Figure 30: Top Challenges in the IVDR Compliance
  • Figure 31: Key Area of Focus by Next-Generation IVD Companies
  • Figure 32: Next-Generation IVD Market (by Region), Share (%), 2022
  • Figure 33: Next-Generation IVD Market (by Region), $Billion, 2022-2033
  • Figure 34: Europe Next-Generation IVD Market, $Billion, 2022-2033
  • Figure 35: Europe Next-Generation IVD Market (by End User), $Billion, 2022-2033
  • Figure 36: Europe Next-Generation IVD Market (by Type), $Billion, 2022-2033
  • Figure 37: Europe Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
  • Figure 38: Europe Next-Generation IVD Market (by Country), $Billion, 2022-2033
  • Figure 39: Germany Next-Generation IVD Market, $Billion, 2022-2033
  • Figure 40: Germany Next-Generation IVD Market (by End User), $Billion, 2022-2033
  • Figure 41: Germany Next-Generation IVD Market (by Type), $Billion, 2022-2033
  • Figure 42: Germany Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
  • Figure 43: France Next-Generation IVD Market, $Billion, 2022-2033
  • Figure 44: France Next-Generation IVD Market (by End User), $Billion, 2022-2033
  • Figure 45: France Next-Generation IVD Market (by Type), $Billion, 2022-2033
  • Figure 46: France Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
  • Figure 47: U.K. Next-Generation IVD Market, $Billion, 2022-2033
  • Figure 48: U.K. Next-Generation IVD Market (by End User), $Billion, 2022-2033
  • Figure 49: U.K. Next-Generation IVD Market (by Type), $Billion, 2022-2033
  • Figure 50: U.K. Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
  • Figure 51: Italy Next-Generation IVD Market, $Billion, 2022-2033
  • Figure 52: Italy Next-Generation IVD Market (by End User), $Billion, 2022-2033
  • Figure 53: Italy Next-Generation IVD Market (by Type), $Billion, 2022-2033
  • Figure 54: Italy Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
  • Figure 55: Spain Next-Generation IVD Market, $Billion, 2022-2033
  • Figure 56: Spain Next-Generation IVD Market (by End User), $Billion, 2022-2033
  • Figure 57: Spain Next-Generation IVD Market (by Type), $Billion, 2022-2033
  • Figure 58: Spain Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
  • Figure 59: Rest-of-Europe Next-Generation IVD Market, $Billion, 2022-2033
  • Figure 60: Rest-of-Europe Next-Generation IVD Market (by End User), $Billion, 2022-2033
  • Figure 61: Rest-of-Europe Next-Generation IVD Market (by Type), $Billion, 2022-2033
  • Figure 62: Rest-of-Europe Next-Generation Core Laboratory IVD Market (by Type), $Billion, 2022-2033
  • Figure 63: Total Number of Companies Profiled
  • Figure 64: bioMerieux SA (BioFire Diagnostics): Product Portfolio
  • Figure 65: bioMerieux SA (BioFire Diagnostics): Overall Financials, $Million, 2020-2022
  • Figure 66: bioMerieux SA (BioFire Diagnostics): Revenue (by Segment), $Million, 2020-2022
  • Figure 67: bioMerieux SA (BioFire Diagnostics): Revenue (by Region), $Million, 2020-2022
  • Figure 68: bioMerieux SA (BioFire Diagnostics): R&D Expenditure, $Million, 2020-2022
  • Figure 69: F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Figure 70: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2020-2022
  • Figure 71: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2020-2022
  • Figure 72: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2020-2022
  • Figure 73: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2020-2022
  • Figure 74: QIAGEN N.V.: Product Portfolio
  • Figure 75: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
  • Figure 76: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
  • Figure 77: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
  • Figure 78: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
  • Figure 79: Siemens Healthineers AG: Product Portfolio
  • Figure 80: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
  • Figure 81: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
  • Figure 82: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
  • Figure 83: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Impact Analysis of Market Drivers, and Restraints on the Europe Next-Generation IVD Market
  • Table 2: Impact of COVID-19 on Different Countries
  • Table 3: Likert Scale
  • Table 4: Impact Analysis of Market Drivers
  • Table 5: Impact Analysis of Market Restraints
  • Table 6: Impact Analysis of Market Opportunities
  • Table 7: Technology Offered by Next-Generation IVD Ecosystem
  • Table 8: Examples of Expansion Strategy by Next-Generation IVD Market Players
  • Table 9: Europe: Market Dynamics
目次
Product Code: BHP1842S

“The Europe Next-Generation IVD Market Expected to Reach $40.41 Billion by 2033.”

Introduction to Europe Next-Generation IVD (In vitro diagnostics) Market

The Europe next-generation IVD market was valued at $24.20 billion in 2023 and is expected to reach $40.41 billion by 2033, growing at a CAGR of 5.26% between 2023 and 2033. The utilization of emerging technologies and innovations in diagnostics has the capacity to stimulate the expansion of the next-generation IVD (In Vitro Diagnostic) market. Molecular diagnostics, genomics, and Next-Generation Sequencing (NGS) are anticipated to be key drivers of this growth, offering fresh opportunities for enhanced disease diagnosis and, consequently, reshaping patient outcomes.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$24.20 Billion
2033 Forecast$40.41 Billion
CAGR5.26%

Market Introduction

The Europe Next-Generation IVD (In Vitro Diagnostics) Market is witnessing significant growth and transformation. It encompasses a diverse range of advanced diagnostic technologies and tools that are revolutionizing healthcare practices in the region. Key factors driving this market include the increasing prevalence of chronic diseases, rising demand for personalized medicine, and a growing emphasis on early disease detection and management. Molecular diagnostics, genomics, and Next-Generation Sequencing (NGS) are at the forefront of innovation, enabling healthcare professionals to obtain precise insights into patients' conditions. These technologies offer enhanced accuracy, speed, and efficiency in diagnosing various diseases, including cancer, infectious diseases, and genetic disorders.

Moreover, the Europe market is characterized by robust research and development activities, fostering continuous advancements in IVD solutions. Regulatory support and stringent quality standards ensure the safety and efficacy of these diagnostics. With a focus on improving patient outcomes and optimizing healthcare resources, the Europe Next-Generation IVD Market is poised for continued growth and innovation, contributing to the region's overall healthcare excellence.

Market Segmentation:

Segmentation 1: by Type

  • Core Laboratory Diagnostics
  • POC Testing
  • Molecular Diagnostics

Segmentation 2: by End User

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutions
  • Other End Users

Segmentation 3: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The Europe next-generation IVD market has been extensively segmented on the basis of various categories, such as type and end user. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe next-generation IVD market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the Europe next-generation IVD market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Table of Contents

Executive Summary

1. Markets

  • 1.1. Market Scope
    • 1.1.1. Key Questions Answered in the Report
  • 1.2. Research Methodology
    • 1.2.1. Next-Generation IVD Market: Research Methodology
    • 1.2.2. Data Sources
      • 1.2.2.1. Primary Data Sources
      • 1.2.2.2. Secondary Data Sources
    • 1.2.3. Market Estimation Model
    • 1.2.4. Criteria for Company Profiling

2. Market Overview

  • 2.1. Introduction
    • 2.1.1. Next-Generation IVD Market Outlook
      • 2.1.1.1. POC-IVD
      • 2.1.1.2. Diagnostic Expenditures
      • 2.1.1.3. Pricing Patterns of Next-Generation IVD
    • 2.1.2. Market Size and Growth Potential
      • 2.1.2.1. Short-Term Impact (2020-2025)
      • 2.1.2.2. Long-Term Impact (2026-2033)
    • 2.1.3. Product Benchmarking by Next- Generation In-vitro Diagnostics Market, (by Type)
  • 2.2. COVID-19 Impact on the Next-Generation IVD Market
    • 2.2.1. Impact on Operations
    • 2.2.2. COVID-19 Impact: Current Scenario of the Market
    • 2.2.3. Pre-COVID Assessment
    • 2.2.4. Post-COVID-19 Market Assessment

3. Industry Analysis

  • 3.1. Legal Requirements
    • 3.1.1. Legal Requirements and Framework in Europe

4. Market Dynamics

  • 4.1. Overview
  • 4.2. Impact Analysis
  • 4.3. Market Drivers
    • 4.3.1. Technological Advancements in Next-Generation In-Vitro Diagnostics Transforming Healthcare System
    • 4.3.2. Rising Demand of POC Testing Boosting Next-Generation IVD Market
    • 4.3.3. Growing Incidence of Chronic and Acute Diseases Demanding for Early Treatment
    • 4.3.4. Boost in the Next-Generation IVD Market during COVID-19 Pandemic
  • 4.4. Market Challenges
    • 4.4.1. Regulatory Hurdles Related to Next-Generation IVD Technologies
    • 4.4.2. Poor Reimbursement Scenario
  • 4.5. Market Opportunities
    • 4.5.1. Rising Number of Next-Generation IVD Companies Involved in Business Expansion
    • 4.5.2. Inclination of Emerging Companies toward Next-Generation IVD

5. Next-Generation IVD Market, by Region, $Million, 2022-2033

  • 5.1. Overview
  • 5.2. Europe
    • 5.2.1. Market Dynamics
    • 5.2.2. Market Size and Forecast
      • 5.2.2.1. Europe Next-Generation IVD Market (by End User)
      • 5.2.2.2. Europe Next-Generation IVD Market (by Type)
        • 5.2.2.2.1. Europe Next-Generation Core Laboratory IVD Market, (by Type)
      • 5.2.2.3. Europe Next-Generation IVD Market (by Country)
        • 5.2.2.3.1. Germany
          • 5.2.2.3.1.1. Market Size and Forecast
          • 5.2.2.3.1.1.1. Germany Next-Generation IVD Market (by End User)
          • 5.2.2.3.1.1.2. Germany Next-Generation IVD Market (by Type)
        • 5.2.2.3.2. France
          • 5.2.2.3.2.1. Market Size and Forecast
          • 5.2.2.3.2.1.1. France Next-Generation IVD Market (by End User)
          • 5.2.2.3.2.1.2. France Next-Generation IVD Market (by Type)
        • 5.2.2.3.3. U.K.
          • 5.2.2.3.3.1. Market Size and Forecast
          • 5.2.2.3.3.1.1. U.K. Next-Generation IVD Market (by End User)
          • 5.2.2.3.3.1.2. U.K. Next-Generation IVD Market (by Type)
        • 5.2.2.3.4. Italy
          • 5.2.2.3.4.1. Market Size and Forecast
          • 5.2.2.3.4.1.1. Italy Next-Generation IVD Market (by End User)
          • 5.2.2.3.4.1.2. Italy Next-Generation IVD Market (by Type)
        • 5.2.2.3.5. Spain
          • 5.2.2.3.5.1. Market Size and Forecast
          • 5.2.2.3.5.1.1. Spain Next-Generation IVD Market (by End User)
          • 5.2.2.3.5.1.2. Spain Next-Generation IVD Market (by Type)
        • 5.2.2.3.6. Rest-of-Europe
          • 5.2.2.3.6.1. Market Size and Forecast
          • 5.2.2.3.6.1.1. Rest-of-Europe Next-Generation IVD Market (by End User)
          • 5.2.2.3.6.1.2. Rest-of-Europe Next-Generation IVD Market (by Type)

6. Company Profiles

  • 6.1. Overview
  • 6.2. bioMerieux SA (BioFire Diagnostics)
    • 6.2.1. Company Overview
    • 6.2.2. Role of bioMerieux SA (BioFire Diagnostics) in the Next-Generation IVD Market
    • 6.2.3. Financials
    • 6.2.4. Recent Developments
      • 6.2.4.1. Corporate Strategies
      • 6.2.4.2. Business Strategies
    • 6.2.5. Analyst Perspective
  • 6.3. F. Hoffmann-La Roche Ltd. (Roche Molecular Systems, Inc.)
    • 6.3.1. Company Overview
    • 6.3.2. Role of F. Hoffmann-La Roche Ltd. in the Next-Generation IVD Market
    • 6.3.3. Financials
    • 6.3.4. Recent Developments
      • 6.3.4.1. Business Strategies
    • 6.3.5. Analyst Perspective
  • 6.4. QIAGEN N.V.
    • 6.4.1. Company Overview
    • 6.4.2. Role of QIAGEN N.V. in the Next-Generation IVD Market
    • 6.4.3. Financials
    • 6.4.4. Recent Developments
      • 6.4.4.1. Corporate Strategies
      • 6.4.4.2. Business Strategies
    • 6.4.5. Analyst Perspective
  • 6.5. Siemens Healthineers AG
    • 6.5.1. Company Overview
    • 6.5.2. Role of Siemens Healthineers AG in the Next-Generation IVD Market
    • 6.5.3. Financials
    • 6.5.4. Recent Developments
      • 6.5.4.1. Corporate Strategies
      • 6.5.4.2. Business Strategies
    • 6.5.5. Analyst Perspective